These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 27506431)
1. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431 [TBL] [Abstract][Full Text] [Related]
2. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
3. [ Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676 [No Abstract] [Full Text] [Related]
6. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197 [No Abstract] [Full Text] [Related]
8. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285 [TBL] [Abstract][Full Text] [Related]
9. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country. Parveen A; Fatima A; Fatima I; Khan IU; Shahid A Nucl Med Commun; 2023 Oct; 44(10):876-887. PubMed ID: 37440195 [TBL] [Abstract][Full Text] [Related]
12. Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539 [TBL] [Abstract][Full Text] [Related]
13. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
14. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618 [TBL] [Abstract][Full Text] [Related]
15. Clinical Experience with [ Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050 [TBL] [Abstract][Full Text] [Related]
17. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
18. Examining Absorbed Doses of Indigenously Developed Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495 [No Abstract] [Full Text] [Related]
19. [ Satapathy S; Yadav MP; Ballal S; Sahoo RK; Bal C Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2495-2503. PubMed ID: 38467922 [TBL] [Abstract][Full Text] [Related]
20. First-in-human study of Zang J; Fan X; Wang H; Liu Q; Wang J; Li H; Li F; Jacobson O; Niu G; Zhu Z; Chen X Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):148-158. PubMed ID: 30090965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]